Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Pulse Biosciences, Inc.    PLSE

PULSE BIOSCIENCES, INC.

(PLSE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Pulse Biosciences : to Participate in Upcoming Investor Conferences

11/11/2020 | 04:06pm EST

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in three upcoming virtual investor conferences.

Management is scheduled to present at the Stifel Healthcare Conference on Tuesday, November 17, 2020 at 4:00pm ET.

Management is scheduled to present at the Stephens Annual Investment Conference on Thursday, November 19, 2020 at 4:00pm ET.

Management is also scheduled to participate in the Piper Sandler Healthcare Conference hosting one-on-one meetings Tuesday, December 1, 2020. A presentation webcast will be available in advance of the event on Monday, November 23, 2020 at 10:00am ET.

Interested parties may access a live and recorded webcast from all conferences on the “Investors” section of the Company’s website at www.pulsebiosciences.com.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. If cleared, the CellFX® System will be the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. Subject to regulatory approval, the initial commercial use of the CellFX System is expected to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across a spectrum of clinical applications. To learn more please visit www.pulsebiosciences.com.

Caution: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation technology are for investigational use only.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.


© Business Wire 2020
All news about PULSE BIOSCIENCES, INC.
01/12PULSE BIOSCIENCES : Updates on CellFX System Regulatory and Clinical Study Progr..
BU
01/05PULSE BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
01/05PULSE BIOSCIENCES, INC. : Announces Redemption of Warrants
BU
2020PULSE BIOSCIENCES : Grants Equity Incentive Awards To New Employees
BU
2020PULSE BIOSCIENCES : Presents Update on Nano-Pulse Stimulation™ Technology ..
BU
2020PULSE BIOSCIENCES : to Participate in Upcoming Investor Conferences
BU
2020PULSE BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
2020PULSE BIOSCIENCES, INC. : Results of Operations and Financial Condition, Financi..
AQ
2020PULSE BIOSCIENCES : Reports Third Quarter 2020 Financial Results
BU
2020PULSE BIOSCIENCES : Schedules Third Quarter 2020 Financial Results Conference Ca..
BU
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 - - -
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 683 M 683 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 263x
Nbr of Employees 82
Free-Float 50,4%
Chart PULSE BIOSCIENCES, INC.
Duration : Period :
Pulse Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PULSE BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 16,00 $
Last Close Price 26,94 $
Spread / Highest target -40,6%
Spread / Average Target -40,6%
Spread / Lowest Target -40,6%
Managers and Directors
NameTitle
Darrin R. Uecker President, Chief Executive Officer & Director
Robert William Duggan Chairman
Edison Manuel Vice President-Operations
Sandra A. Gardiner CFO, Secretary, Treasurer & Executive VP-Finance
Richard Nuccitelli Chief Science Officer
Sector and Competitors